Valeant in $5.7 Billion Unsolicited Takeover Offer and Consent Solicitation to Replace Directors of Cephalon

Cleary Gottlieb is representing Goldman Sachs, as financial advisor to Valeant Pharmaceuticals in connection with its unsolicited proposal, valued at $5.7 billion, to acquire Cephalon for $73 per share and a related consent solicitation to replace the directors of Cephalon.

Valeant is a multinational specialty pharmaceutical company. Cephalon is global biopharmaceutical company.